Stock Repurchase Program Announced by Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Board

Lakefront Biotherapeutics American Depositary Shares logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Lakefront approved a $54.95 million share repurchase program, allowing it to buy back up to 2.5% of its outstanding shares on the open market.
  • Analyst views were mixed: TD Cowen initiated coverage with a “strong buy,” while Morgan Stanley maintained “equal weight” despite raising its target to $27. MarketBeat’s consensus rating was “Moderate Buy,” with an average price target of $36.
  • For the latest quarter, Lakefront reported a loss of $0.05 per share and revenue of $7.87 million.
  • Interested in Lakefront Biotherapeutics American Depositary Shares? Here are five stocks we like better.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) declared that its board has approved a share repurchase program on Monday, November 16th, RTT News reports. The company plans to repurchase $54.95 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 2.5% of its shares through open market purchases. Share repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LKFT. Morgan Stanley boosted their target price on shares of Lakefront Biotherapeutics American Depositary Shares from $26.00 to $27.00 and gave the company an "equal weight" rating in a research note on Monday. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, October 2nd. Raymond James Financial reaffirmed a "market perform" rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Thursday. TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday. They issued a "strong-buy" rating for the company. Finally, Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a "sector perform" rating to an "outperform" rating and boosted their price objective for the company from $26.00 to $45.00 in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.00.

Read Our Latest Stock Analysis on LKFT

Lakefront Biotherapeutics American Depositary Shares Price Performance

Shares of NASDAQ LKFT traded up $0.81 during mid-day trading on Monday, hitting $34.79. The company had a trading volume of 292,601 shares, compared to its average volume of 265,015. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -24.67 and a beta of 0.22. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $36.24. The firm's 50 day simple moving average is $30.49 and its two-hundred day simple moving average is $29.94.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $7.87 million during the quarter. Equities analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.46 earnings per share for the current year.

Lakefront Biotherapeutics American Depositary Shares News Roundup

Investors following LKFT have been watching these news items:

  • Positive Sentiment: Lakefront launched a new buyback of up to €50 million after completing its previous €50 million program. The company says it may repurchase up to 2.5% of its shares, a move that can signal management confidence and support demand for the stock. Lakefront Initiates New €50 Million Share Repurchase Program
  • Positive Sentiment: TD Cowen initiated coverage with a “strong buy” rating, adding a bullish analyst view. TD Cowen coverage reported by Zacks
  • Negative Sentiment: Morgan Stanley raised its price target from $26 to $27 but kept an “equal weight” rating. The target remains about 22.4% below the cited share price, suggesting the firm sees downside from current levels.

Lakefront Biotherapeutics American Depositary Shares Company Profile

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lakefront Biotherapeutics American Depositary Shares Right Now?

Before you consider Lakefront Biotherapeutics American Depositary Shares, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lakefront Biotherapeutics American Depositary Shares wasn't on the list.

While Lakefront Biotherapeutics American Depositary Shares currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines